Andrew Sneddon
Chairman

Andrew was appointed to the Board of Elastagen Pty Ltd as Chairman in September 2008. Andrew is a former partner of PricewaterhouseCoopers (PWC). In his PWC role, Andrew led the technology practise for a period of time and specialised in fast growth and emerging technology companies working with many companies from start-ups to successful global corporations.

In more recent years he was the partner leading the firm's Australian Life Sciences Practice. Andrew has extensive experience in a wide range of technical areas including mergers and acquisitions, business and strategic planning, audit, valuation, capital raising and stock exchange listings on the Australian, NASDAQ and London Stock Exchanges.

He has worked across a broad range of industries and is currently the chairman of MIRteq Pty Ltd, CustomWare Pty Ltd, InterAcct Solutions Pte and TGR BioSciences Pty Ltd. He is also a member of the Audit and Compliance Committees of the Crescent Capital Private Equity Funds.

Read more… Hide this…

Xavier Yon
Non-Executive Director

Xavier Yon is a seasoned healthcare executive with an extensive background in dermatology. Previous roles include executive positions with Pfizer, Solvay, Alcon and most notably as CEO of Galderma for 17 years. During his time at Galderma he built the company from its initial spin out from Alcon to be a world leader in ethical dermatology.

Galderma currently has over 3,000 employees and $2 Billion in revenue. More recently Xavier has served as a Director of Graceway Pharmaceuticals (USA), which was acquired by Medicis in 2011. In addition to his position with Elastagen, Xavier currently serves as a board member of Photocure (Norway), a pioneer of Photo Dynamic Therapy, and Virbac (France), a global leader in animal health.

Xavier holds a degree in Physics, Chemistry and Biology from Sorbonne University, Paris and attended the Advanced Management Program at Harvard University.

Read more… Hide this…

Dr Steve Gourlay
Director

Dr Steve Gourlay is a partner at GBS Ventures Partners, Australia’s largest life sciences venture firm. He has more than 20 years experience in drug and medical device development (Monash University, University of California, San Francisco, Genentech, Life Science Angels).

At Genentech he contributed to the preclinical and clinical sections of successful new drug applications for Xolair™, Avastin™, and Raptiva™ and supervised six IND applications. Steve is on the board of directors of six early stage medical technology companies in Australia and the USA and is a consultant physician in Internal & Vascular Medicine.

He received his PhD in Medicine from Monash University (clinical epidemiology, clinical trial methodology), his postdoc from UCSF (Phase I studies) and his MBA from Macquarie University.

Read more… Hide this…

Stephen Thompson
Director

Stephen is a founding partner of Brandon Capital Partners. Prior to moving to Australia in 2004 Stephen was a Director of Apax Partners, a leading international private equity group. Before joining Apax Partners, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals.

Earlier, Stephen spent ten years as a research immunologist in both London and California. Stephen is a Director of MiReven Pty Ltd and the Cancer Therapeutics CRC. Stephen has an honours degree in immunology and biochemistry, a PhD in immunology from Kings College London and an MBA from Imperial College London.

Stephen is a member of the Australian Institute of Company Directors and of AusBiotech.

Read more… Hide this…

Hamish Hawthorn
Director

Hamish is the Chief Executive Officer of ATP Innovations – Australia’s leading business incubator. ATP Innovations delivers commercialisation and business expertise to emerging technology businesses, helping entrepreneurs build successful high-growth companies. Hamish has been involved in the commercialisation of technology for over 15 years with experience in the advanced manufacturing and life sciences sectors.

In 2008, Hamish co-founded Sydney Angels, a formal angel group that invests in Australian technology companies. Prior to joining ATP Innovations, Hamish directed strategic business development programs for a number of Australian technology companies. Hamish is a Visiting Fellow in the Entrepreneurs in Science Program at the University of New South Wales, and teaches entrepreneurship at the University of Sydney, the University of Technology, Sydney and the Australian National University.

He is a qualified mechanical engineer with postgraduate training in business and technology.

Read more… Hide this…

Robert Daniels
Director & CEO

Robert has successfully guided Elastagen from its early research phases through to the current clinical development of its Elastatherapy™ treatments for the rapidly growing cosmetic and medical dermatology markets.

Prior to joining Elastagen Robert had spent the previous 10 years working across a broad range of the life science industry including contract research, medical devices and therapeutics. He has been successful in raising capital; manageing in- and out- licensing programs; joint venture creation; and, manageing product development programs through to the clinic. Robert’s experience includes University spin-outs through to listed companies; and, he has worked in the UK, Australia and Hong Kong.

Most recently he was VP Asia Pacific for PharmaVentures Ltd, a boutique transaction advisory firm specialising in the life sciences. Prior to that Robert was Chief Commercial Officer at Novathera Ltd where he gained significant domain experience in the regenerative medicine field.

Robert has a PhD from University College London and a Masters in Entrepreneurship and Innovation from the Australian Graduate School of Entrepreneurship.

Read more… Hide this…